Renault to Bolster Robotics with Venture Capital to Start-Up
### Renault and Wandercraft Partner for Next-Generation Robots in Industrial Production
In a groundbreaking move, French automotive giant Renault and robotics company Wandercraft have deepened their collaboration in 2025, focusing on the development of next-generation industrial robots. The partnership, which has already yielded significant results, includes the unveiling of Calvin - a new industrial humanoid robot designed for factory environments.
Calvin, co-developed with Renault, marks a major step for Wandercraft, traditionally known for its medical exoskeletons. The humanoid robot is intended to work alongside human employees, with Renault announcing plans to roll out Calvin robots across its manufacturing facilities. The aim is to leverage mass-production and cost-reduction techniques to scale up production, positioning this move as a forward-looking strategy by Renault's leadership.
While Calvin is a new industrial product, Wandercraft continues its work on medical exoskeletons. The company's background in rehabilitative robotics informs its approach to industrial robotics, emphasizing safe, intuitive human-robot interaction. Wandercraft is also planning to bring a new exoskeleton named Eve to the market.
The partnership is not only benefiting Renault, but also opening new business opportunities for Wandercraft in the robotics market. Thierry Charvet, chief industry and quality officer for Renault, has made a statement about the partnership, expressing expectations of productivity gains through the acceleration of production time and costs reduction. The project aims to relieve Renault's workers from onerous, non-ergonomic tasks and increase productivity.
The collaboration between Renault and Wandercraft is expected to set new standards for human-robot collaboration in manufacturing, with potential ripple effects across both industrial and medical robotics sectors. Wandercraft recently raised $75 million to support its expansion into industrial robotics and scale its existing medical exoskeleton business, underscoring the company's dual-track strategy.
Here's a summary of the key aspects of the partnership:
| Aspect | Details | |---------------------------|-----------------------------------------------------------------------------------------| | New Product | Calvin industrial humanoid robot, co-developed with Renault | | Industrial Application | Rollout planned on Renault factory floors; mass production and cost reduction emphasized | | Medical Exoskeleton | Ongoing development and commercialization of assistive devices | | Funding | $75 million raised for expansion into industrial robotics and scaling exoskeletons | | Future Goals | Broader industrial deployment, potential to supply other sectors |
As both companies move forward, the Renault-Wandercraft partnership is poised to drive innovation and productivity in the fields of industrial and medical robotics.
The collaboration between Renault and Wandercraft, initiated for next-generation robots in industrial production, is also resulting in investments in technology, as Wandercraft recently raised $75 million to support their expansion into industrial robotics. In the realm of finance, this venture is expected to yield productivity gains through the acceleration of production and cost reduction. simultaneously, Wandercraft continues its work in the healthcare industry, planning to bring a new medical exoskeleton named Eve to the market.
